A Cluster Analysis of Bronchiectasis Patients Based on the Airway Immune Profile
- PMID: 33217421
- DOI: 10.1016/j.chest.2020.11.011
A Cluster Analysis of Bronchiectasis Patients Based on the Airway Immune Profile
Abstract
Background: Clinical heterogeneity in bronchiectasis remains a challenge for improving the appropriate targeting of therapies and patient management. Antimicrobial peptides (AMPs) have been linked to disease severity and phenotype.
Research question: Can we identify clusters of patients based on the levels of AMPs, airway inflammation, tissue remodeling, and tissue damage to establish their relationship with disease severity and clinical outcomes?
Study design and methods: A prospective cohort of 128 stable patients with bronchiectasis were recruited across three centers in three different countries (Spain, Scotland, and Italy). A two-step cluster strategy was used to stratify patients according to levels of lactoferrin, lysozyme, LL-37, and secretory leukocyte protease inhibitor in sputum. Measurements of inflammation (IL-8, tumor growth factor β, and IL-6), tissue remodeling and damage (glycosaminoglycan, matrix metallopeptidase 9, neutrophil elastase, and total and bacterial DNA), and neutrophil chemotaxis were assessed.
Results: Three clusters of patients were defined according to distinct airway profiles of AMPs. They represented groups of patients with gradually distinct airway infection and disease severity. Each cluster was associated with an airway profile of inflammation, tissue remodeling, and tissue damage. The relationships between soluble mediators also were distinct between clusters. This analysis allowed the identification of the cluster with the most deregulated local innate immune response. During follow-up, each cluster showed different risk of three or more exacerbations occurring (P = .03) and different times to first exacerbations (P = .03).
Interpretation: Bronchiectasis patients can be stratified in different clusters according to profiles of airway AMPs, inflammation, tissue remodeling, and tissue damage. The combination of these immunologic variables shows a relationship with disease severity and future risk of exacerbations.
Keywords: airway immunity; bronchiectasis; cluster analysis; exacerbations.
Copyright © 2020 American College of Chest Physicians. Published by Elsevier Inc. All rights reserved.
Similar articles
-
Antimicrobial peptides, disease severity and exacerbations in bronchiectasis.Thorax. 2019 Sep;74(9):835-842. doi: 10.1136/thoraxjnl-2018-212895. Epub 2019 Jul 5. Thorax. 2019. PMID: 31278172
-
A point-of-care neutrophil elastase activity assay identifies bronchiectasis severity, airway infection and risk of exacerbation.Eur Respir J. 2019 Jun 13;53(6):1900303. doi: 10.1183/13993003.00303-2019. Print 2019 Jun. Eur Respir J. 2019. PMID: 31151955
-
Neutrophil Elastase Activity Is Associated with Exacerbations and Lung Function Decline in Bronchiectasis.Am J Respir Crit Care Med. 2017 May 15;195(10):1384-1393. doi: 10.1164/rccm.201605-1027OC. Am J Respir Crit Care Med. 2017. PMID: 27911604 Free PMC article.
-
Neutrophilic inflammation in bronchiectasis.Eur Respir Rev. 2025 Apr 2;34(176):240179. doi: 10.1183/16000617.0179-2024. Print 2025 Apr. Eur Respir Rev. 2025. PMID: 40174958 Free PMC article. Review.
-
Mechanisms of immune dysfunction and bacterial persistence in non-cystic fibrosis bronchiectasis.Mol Immunol. 2013 Aug;55(1):27-34. doi: 10.1016/j.molimm.2012.09.011. Epub 2012 Oct 22. Mol Immunol. 2013. PMID: 23088941 Review.
Cited by
-
Pathophysiology and genomics of bronchiectasis.Eur Respir Rev. 2024 Jul 3;33(173):240055. doi: 10.1183/16000617.0055-2024. Print 2024 Jul. Eur Respir Rev. 2024. PMID: 38960613 Free PMC article. Review.
-
Peripheral Neutrophil-to-Lymphocyte Ratio in Bronchiectasis: A Marker of Disease Severity.Biomolecules. 2022 Sep 30;12(10):1399. doi: 10.3390/biom12101399. Biomolecules. 2022. PMID: 36291608 Free PMC article.
-
[The expression and role of interleukin-8 in chronic rhinosinusitis].Lin Chuang Er Bi Yan Hou Tou Jing Wai Ke Za Zhi. 2021 Aug;35(8):765-768. doi: 10.13201/j.issn.2096-7993.2021.08.020. Lin Chuang Er Bi Yan Hou Tou Jing Wai Ke Za Zhi. 2021. PMID: 34304543 Free PMC article. Review. Chinese.
-
Systemic Inflammatory Biomarkers Define Specific Clusters in Patients with Bronchiectasis: A Large-Cohort Study.Biomedicines. 2022 Jan 21;10(2):225. doi: 10.3390/biomedicines10020225. Biomedicines. 2022. PMID: 35203435 Free PMC article.
-
Rationale and Clinical Use of Bronchodilators in Adults with Bronchiectasis.Drugs. 2022 Jan;82(1):1-13. doi: 10.1007/s40265-021-01646-3. Epub 2021 Nov 26. Drugs. 2022. PMID: 34826104
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources